Seronegative Myasthenia Gravis and Graves’ Disease. Is there a link?

Abstract

Graves’ disease (GD) and myasthenia gravis (MG) are common autoimmune diseases but their coexistence is very rare. They may possibly share the same pathogenetic mechanisms. Recent research has shown the involvement of autoantibodies, lymphocytes, cytokines and chemokines in the pathogenesis of MG and GD. It appears that Th17 cell lineage is involved in autoimmune thyroid disease (AITD) and seems to be key factor in the development of both MG and GD.

A 34-year-old male with seronegative myasthenia gravis due to thymic hyperplasia was diagnosed with also GD and opthalmopathy. Several diagnostic and therapeutic issues regarding the relevant literature are discussed.

Key words

Graves-disease - Graves opthalmopathy - myasthenia Gravis - thymic hyperpalasia - periodic hypokalemic paralyis

• References

• 1 Chen Z, O’Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res 2008; 41: 87-102
• 2 Drachman B. Myasthenia gravis and the thyroid gland. N Engl J Med 1962; 266: 330-333
• 3 Dupond JL, Essalmi L, Gil H et al. Rituximab treatment of stiff-person syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J Clin Neurosci 2010; 17: 389-391
• 4 Eymard B. Antibodies in myasthenia gravis. Rev Neurol (Paris) 2009; 165: 137-143
• 5 Figueroa-Vega N, Alfonso-Pιrez M, Benedicto I et al. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis. J Clin Endocrinol Metab 2010; 95: 953-962
• 6 Garlepp MJ, Dawkins RL, Christiansen FT. Autoimmunity in ocular and generalized myasthenia gravis. J Neuroimmunol 1981; 1: 325-332
• 7 Hegedόs L, Smith TJ, Douglas RS et al. Targeted biological therapies for Graves’ disease and thyroid associated ophthalmopathy. Focus on B cell depletion with Rituximab. Clin Endocrinol (Oxf) 2010; [Epub ahead of print]
• 8 Huang S, Tan LM. Research advancement in immunopathogenesis of myasthenia gravis. Neurosci Bull 2010; 26: 85-89
• 9 Karni A, Zisman E, Katz-Levy Y et al. Reactivity of T cells from seronegative patients with myasthenia gravis to T cell epitopes of the human acetylcholine receptor. Neurology 1997; 48: 1638-1642
• 10 Kida K, Hayashi M, Yamada I et al. Heterogeneity in myasthenia gravis: HLA phenotypes and autoantibody responses in ocular and generalized types. Ann Neurol 1987; 21: 274-278
• 11 Kiessling WR, Fink ER, Kotulla P et al. Circulating TSH-binding inhibiting immunoglobulins in myasthenia gravis. Acta Endocrinol 1982; 101: 41-46
• 12 Lin SH. Thyrotoxic periodic paralysis. Mayo Clin Proc 2005; 80: 99-105
• 13 Lin SH, Chu P, Cheng CJ et al. Early diagnosis of thyrotoxic periodic paralysis: spot urine calcium to phosphate ratio. Crit Care Med 2006; 34: 2984-2989
• 14 Masuda M, Matsumoto M, Tanaka S et al. Clinical implication of peripheral CD4(+), CD25(+) regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol 2010; [Epub ahead of print]
• 15 Milliken CH, Haines SF. Thyroid gland in relation to neuromuscular disease. Arch Intern Med 1953; 92: 5-39
• 16 Nakamura H, Usa T, Motomura M et al. Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. J Endocrinol Invest 2008; 31: 861-865
• 17 Nanba T, Watanabe M, Inoue N et al. Increases of the Th1/Th2 cell ratio in severe Hashimoto’s disease and in the proportion of Th17 cells in intractable Graves’ disease. Thyroid 2009; 19: 495-501
• 18 Nicolle MW. Pseudo-myasthenia gravis and thymic hyperplasia in Graves’ disease. Can J Neurol Sci 1999; 26: 201-203
• 19 Puvanendran K, Cheah JS, Naganathan N et al. Neuromuscular transmission in thyrotoxicosis. J Neurol Sci 1979; 43: 47-57
• 20 Quadbeck B, Hoermann R, Roggenbuck U et al. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves’ disease. Thyroid 2005; 15: 1047-1054
• 21 Sadnicka A, Reilly MM, Mummery C et al. Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis. J Neurol Neurosurg Psychiatry 2010; [Epub ahead of print]
• 22 Scherer K, Bedlack RS, Simel DL. Does this patient have myasthenia gravis?. JAMA 2005; 293: 1906-1914
• 23 Scuderi F, Marino M, Colonna L et al. Anti-p110 autoantibodies identify a subtype of “seronegative” myasthenia gravis with prominent oculobulbar involvement. Lab Invest 2002; 82: 1139-1346
• 24 Tsuda E, Imai T, Matsumura A et al. Thyrotoxic myopathy mimicking myasthenic syndrome associated with thymic hyperplasia. Intern Med 2008; 47: 445-447
• 25 Vincent A, McConville J, Farrugia ME et al. Antibodies in myasthenia gravis and related disorders. Ann N Y Acad Sci 2003; 998: 324-335
• 26 Wu CZ, Wu YK, Lin JD et al. Thyrotoxic periodic paralysis complicated by acute hypercapnic respiratory failure and ventricular tachycardia. Thyroid 2008; 18: 1321-1324